Dr. Burzynski Vindicated

Dr. Stanislaw Burzynski, developer of the non-toxic antineoplastons treatment for cancer, has been the target of repeated attack by the Food & Drug Administration (FDA). In addition to several raids, the agency, along with the U.S. Justice Department, has tried and failed three times to get indictments against Burzynski. One Congressman claims that the agencies are abusing the grand jury process in order to harass and punish Dr. Burzynski.

Some time ago, the FDA allowed Dr. Burzynski to begin trials of his cancer treatment, but the alleged harassment continued nonetheless. For example, the FDA ordered that Burzynski contact each one of the 300 patients enrolled in the study by telephone each day—no messages permitted. There is no reason for this stringent FDA requirement, since the treatment under evaluation is nontoxic.

Now, it seems that Dr. Burzynski will finally receive some recognition for his anti-cancer treatment. Interim results from Phase II clinical trials of his treatment indicate that antineoplastons produced a greater than 50% tumor reduction, or complete tumor elimination, in 43 of 178 evaluable patients. An additional 72 other patients remained stable, meaning that their cancers did not worsen.

Describing his therapy, Burzynski says that the antineoplastons work by turning off the signal that makes cancer cells multiply endlessly, and turning on the signal that tells them to undergo programmed cell death. He describes his treatment as an "information-age approach," because it uses information rather than energy to bring about healing.

The next step is for Burzynski to apply for FDA approval, which could take place by the end of this year.  Based on information in: National Council Against Health Fraud Newsletter, May/June 1998